Reimbursement Considerations In the Treatment of Hypercholesterolemia: Economics and Implications for Medical Groups

The objective of this roundtable discussion is to review the impact of hypercholesterolemia on cardiovascular risk and public health. In addition, participants explore the clinical and pharmacoeconomic profiles of statins and consider their implications for medical group contracts with HMOs. Among the issues discussed:

  • Overview of therapy and dietary factors
  • Risk-factor management
  • Compliance issues
  • HEDIS guidelines
  • Pharmacoeconomic analysis of therapy
  • Utilization drivers
  • Selecting a therapy